Drugs & Therapy Perspectives

, Volume 20, Issue 10, pp 17–20 | Cite as

No sweat — hyperhidrosis can be controlled

Disease Management

Hyperhidrosis is the excessive production of sweat by the eccrine glands in the skin. It occurs in up to 1% of the population and can negatively affect the patient’s social, work or school life, leading to embarrassment and psychological problems. Primary hyperhidrosis affects primarily the palms of the hands, soles of the feet and/or the axillae. Generalised sweating is most often due to an underlying cause, which should be identified and appropriately treated. The range of treatments for primary hyperhidrosis include topical, systemic and surgical options.

Sweat, sweat and more sweat

Sweat production by the eccrine glands in the skin is a normal physiological process that serves to regulate body temperature. Hyperhidrosis is the excessive production of sweat resulting from overactivity of the cholinergic nerves controlling the sweat glands.[1] It affects up to 1% of the population.[2] The condition can affect localised areas (focal) or be generalised.[3]

A primary condition …



  1. 1.
    Connolly M, deBerker D. Management of primary hyperhidrosis: a summary of the different treatment modalities. Am J Clin Dermatol 2003; 4(10); 681–97PubMedCrossRefGoogle Scholar
  2. 2.
    Atkins JL, Butler PE. Hyperhidrosis: a review of current management. Plast Reconstr Surg 2002; 110: 222–8PubMedCrossRefGoogle Scholar
  3. 3.
    Boni R. Generalized hyperhidrosis and its systemic treatment. Curr Probl Dermatol 2002; 30: 44–7PubMedCrossRefGoogle Scholar
  4. 4.
    Adar R, Kurchin A, Zweig A, et al. Palmar hyperhidrosis and its surgical treatment: a report of 100 cases. Ann Surg 1977; 186(1): 34–41PubMedCrossRefGoogle Scholar
  5. 5.
    International Hyperhidrosis Society HCP [online]. Available from URL: [Accessed 2004 Apr 19]
  6. 6.
    Lauchli S, Burg G. Treatment of hyperhidrosis with botulinum toxin A. Skin Therapy Lett 2003; 8(7): 1–4PubMedGoogle Scholar
  7. 7.
    British National Formulary. No. 47. London: The Pharmaceutical Press, 2004 MarGoogle Scholar
  8. 8.
    Sato K, Timm DE, Sato F, et al. Generation and transit pathway of H+ is critical for inhibition of palmar sweating by iontophoresis in water. J Appl Physiol 1993 Nov; 75(5): 2258–64PubMedGoogle Scholar
  9. 9.
    Holzle E. Topical pharmacological treatment. Curr Probl Dermatol 2002; 30: 30–43PubMedCrossRefGoogle Scholar
  10. 10.
    Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 2002 Dec; 249(12): 1729–32PubMedCrossRefGoogle Scholar
  11. 11.
    Shimizu T, Sakaguchi G. Production and properties of type F toxin. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 87–92Google Scholar
  12. 12.
    Hitt, E. Botulinum toxin safe, effective for repeated treatment of hyperhidrosis [online]. Available from URL: [Accessed 2004 Apr 13]
  13. 13.
    Naumann M, et al. Botulinum toxin type A in axillary hyperhidrosis. BMJ 2001; 323: 596–9PubMedCrossRefGoogle Scholar
  14. 14.
    Heckmann M, Ceballos-Baumann A, Plewig G, et al. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001 Feb; 344(7): 488–93PubMedCrossRefGoogle Scholar
  15. 15.
    Huh CH, Han KH, Seo KI, et al. Botulinum toxin treatment for a compensatory hyperhidrosis subsequent to an upper thoracic sympathectomy. Dermatolog Treat 2002; 13: 91–3CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations